19
Table 2: Total pI and PAP Data from iCIEF of On-Board Mixed mAb. The reproducibility of iCIEF separation was determined by % RSD for both pI and PAP for the four main charge variants of bevacizumab.
References
1. G. Galfrè, and C. Milstein. Methods Enzymol. 73 (1981), 3-46.
2. O. H. Brekke, and I. Sandlie. Nat. Rev. Drug Discov. 2 (2003), 52-62.
3. A. Shukla, B. Hubbard, T. Tressel, S. Guhan, and D. Low. J Chromatogr B, 848 (2007), 28–39.
4. R. M. Lewis, and M. E. Cosenza. Regulatory Focus, 16 (2010), 25-29.
5. R. J. Harris. Dev. Biol. 122 (2005), 117-127.
Overall, CEInfinite on-board mixing delivered similar or improved precision, as calculated by % RSD, when compared to premixed sample preparation. For those where results were similar, the premixed variability was slightly lower but arguably not enough to compensate for the increased efficiency made possible by on-board mixing.
Where comparable data was available, the CEInfinite surpassed the analogous instrument except for when calculating the pI of the main acidic peak (acidic 2), where the reported % RSD was 0.0% [10]. Though the identity of the mAb in Sosic et al. was not made available, the mAb used in this study was similar enough for method comparison. It is also interesting to note this outperformance as the Electrophoresis study had twice the sample size (n=12).
Conclusion
Biotherapeutics, including mAbs, continue to gain momentum as an effective medical intervention in a variety of diseases. As biologic production escalates, variations in charge can be introduced with the potential to significantly alter curative efficacy and patient safety. iCIEF is an efficient and robust way to quantify charge heterogeneity in protein therapeutics at any point in development. The CEInfinite Analytical iCIEF instrument from Advanced Electrophoresis Solutions Ltd is equipped with on-board mixing, increasing throughput while maintaining and often improving reproducibility from existing iCIEF methods.
6. P. W. Tebbey, A. Varga, M. Naill, J. Clewell, and J. Venema. MAbs, 7 (2015), 805–11.
7. J. Wu, S. C. Li, and A. Watson. J. Chromatogr. A, 817 (1998), 163-171.
8. Q. Mao, and J. Pawliszyn. J. Biochem. Biophys. Methods, 39 (1999), 93-110.
9. L. Goodridge, C. Goodridge, J. Wu, M. Griffiths, and J. Pawliszyn. Anal. Chem. 76 (2004), 48–52.
10. Z. Sosic, D. Houde, A. Blum, T. Carlage, and Y. Lyubarskaya. Electrophoresis. 29 (2008), 4368-76.
BioLC Innovations... ...with Incredible Reproducibility!
• SEC for high resolved MAbs • HIC with exceptional efficiency
• RP-C4-Widepore with superior stability • IEX for high recovery
Discover more at
www.ymc.de
Proteins Antibodies
Oligonucleotides Peptides
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60
